TP53 and cancer: By disabling key cell death checkpoints—including Nur77 mitochondrial signaling, the MDM2–TP53 axis, and PAR-mediated AIF activation—CHD1L enables cancer cells to survive under conditions of metabolic stress, immune surveillance, and genotoxic therapy.